Literature DB >> 23955390

Formalizing an integrative, multidisciplinary cancer therapy discovery workflow.

Mary F McGuire1, Heiko Enderling, Dorothy I Wallace, Jaspreet Batra, Marie Jordan, Sushil Kumar, John C Panetta, Eddy Pasquier.   

Abstract

Although many clinicians and researchers work to understand cancer, there has been limited success to effectively combine forces and collaborate over time, distance, data, and budget constraints. Here we present a workflow template for multidisciplinary cancer therapy that was developed during the 2nd Annual Workshop on Cancer Systems Biology sponsored by Tufts University, Boston, Massachusetts, in July 2012. The template was applied to the development of a metronomic therapy backbone for neuroblastoma. Three primary groups were identified: clinicians, biologists, and quantitative scientists (mathematicians, computer scientists, and engineers). The workflow described their integrative interactions; parallel or sequential processes; data sources and computational tools at different stages as well as the iterative nature of therapeutic development from clinical observations to in vitro, in vivo, and clinical trials. We found that theoreticians in dialog with experimentalists could develop calibrated and parameterized predictive models that inform and formalize sets of testable hypotheses, thus speeding up discovery and validation while reducing laboratory resources and costs. The developed template outlines an interdisciplinary collaboration workflow designed to systematically investigate the mechanistic underpinnings of a new therapy and validate that therapy to advance development and clinical acceptance. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 23955390      PMCID: PMC4040396          DOI: 10.1158/0008-5472.CAN-13-0310

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.

Authors:  Andreas Peyrl; Monika Chocholous; Mark W Kieran; Amedeo A Azizi; Christina Prucker; Thomas Czech; Karin Dieckmann; Maria-Theresa Schmook; Christine Haberler; Ulrike Leiss; Irene Slavc
Journal:  Pediatr Blood Cancer       Date:  2011-12-06       Impact factor: 3.167

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

3.  The evolution of cancer control research: an international perspective from Canada and the United States.

Authors:  Allan Best; Robert A Hiatt; Roy Cameron; Barbara K Rimer; David B Abrams
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-08       Impact factor: 4.254

4.  The several Cs of translational clinical research.

Authors:  David G Nathan
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.

Authors:  Yaning Wang; A Venkatesh Bhattaram; Pravin R Jadhav; Lawrence J Lesko; Rajanikanth Madabushi; J Robert Powell; Wei Qiu; He Sun; Dong S Yim; Jenny J Zheng; Jogarao V S Gobburu
Journal:  J Clin Pharmacol       Date:  2008-02       Impact factor: 3.126

Review 6.  Dissecting cancer through mathematics: from the cell to the animal model.

Authors:  Helen M Byrne
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

7.  Role of necrosis in regulating the growth saturation of multicellular spheroids.

Authors:  J P Freyer
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

Review 8.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

Review 9.  Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Authors:  Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

Review 10.  NSAIDs in neuroblastoma therapy.

Authors:  John I Johnsen; Magnus Lindskog; Frida Ponthan; Ingvild Pettersen; Lotta Elfman; Abiel Orrego; Baldur Sveinbjörnsson; Per Kogner
Journal:  Cancer Lett       Date:  2005-10-18       Impact factor: 8.679

View more
  8 in total

Review 1.  Metronomics: towards personalized chemotherapy?

Authors:  Nicolas André; Manon Carré; Eddy Pasquier
Journal:  Nat Rev Clin Oncol       Date:  2014-06-10       Impact factor: 66.675

Review 2.  Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.

Authors:  Anna Konstorum; Anthony T Vella; Adam J Adler; Reinhard C Laubenbacher
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

3.  Modeling iontophoretic drug delivery in a microfluidic device.

Authors:  Maryam Moarefian; Rafael V Davalos; Danesh K Tafti; Luke E Achenie; Caroline N Jones
Journal:  Lab Chip       Date:  2020-09-01       Impact factor: 6.799

4.  Role of vascular normalization in benefit from metronomic chemotherapy.

Authors:  Fotios Mpekris; James W Baish; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

5.  A Model for Spheroid versus Monolayer Response of SK-N-SH Neuroblastoma Cells to Treatment with 15-Deoxy-PGJ2.

Authors:  Dorothy I Wallace; Ann Dunham; Paula X Chen; Michelle Chen; Milan Huynh; Evan Rheingold; Olivia Prosper
Journal:  Comput Math Methods Med       Date:  2016-12-01       Impact factor: 2.238

Review 6.  Fighting Cancer with Mathematics and Viruses.

Authors:  Daniel N Santiago; Johannes P W Heidbuechel; Wendy M Kandell; Rachel Walker; Julie Djeu; Christine E Engeland; Daniel Abate-Daga; Heiko Enderling
Journal:  Viruses       Date:  2017-08-23       Impact factor: 5.048

Review 7.  Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis.

Authors:  Mohit Kumar Jolly; Marcelo Boareto; Bin Huang; Dongya Jia; Mingyang Lu; Eshel Ben-Jacob; José N Onuchic; Herbert Levine
Journal:  Front Oncol       Date:  2015-07-20       Impact factor: 6.244

Review 8.  Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues.

Authors:  Munju Kim; Robert J Gillies; Katarzyna A Rejniak
Journal:  Front Oncol       Date:  2013-11-18       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.